2025 United States Anti-Asthma Drugs Market Revenue Opportunities Report
Description
The 2025 United States Anti-Asthma Drugs Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Anti-Asthma Drugs Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the United States Anti-Asthma Drugs Market are GlaxoSmithKline (GSK), Novartis, Pfizer, and Merck. GSK leads with its innovative biologic treatment depemokimab, targeting severe asthma with a long-acting monoclonal antibody enabling six-month dosing, showing strong phase III trial results. Novartis also has a significant presence with a broad respiratory portfolio and ongoing clinical advancements in asthma therapeutics. Pfizer, a global pharmaceutical leader, markets key asthma medicines and pursues development of novel asthma drugs leveraging its R&D capabilities. Merck contributes with established asthma drug products and pipeline candidates addressing various asthma types and severities, supporting its market position in the U.S..
These companies dominate due to their extensive research capabilities, regulatory approvals, and comprehensive marketing and distribution networks in the U.S. Their focus on biologics and targeted therapies, such as monoclonal antibodies, reflects the market trend toward precision medicine for severe asthma cases. The U.S. asthma drug market is growing rapidly, valued at about $8.95 billion in 2023 and forecast to exceed $14.75 billion by 2033, driven by increasing asthma prevalence and demand for advanced treatments. Their active engagement in clinical trials, innovative drug launches, and collaborations ensures ongoing leadership in this rapidly evolving field.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Anti-Asthma Drugs Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the United States Anti-Asthma Drugs Market are GlaxoSmithKline (GSK), Novartis, Pfizer, and Merck. GSK leads with its innovative biologic treatment depemokimab, targeting severe asthma with a long-acting monoclonal antibody enabling six-month dosing, showing strong phase III trial results. Novartis also has a significant presence with a broad respiratory portfolio and ongoing clinical advancements in asthma therapeutics. Pfizer, a global pharmaceutical leader, markets key asthma medicines and pursues development of novel asthma drugs leveraging its R&D capabilities. Merck contributes with established asthma drug products and pipeline candidates addressing various asthma types and severities, supporting its market position in the U.S..
These companies dominate due to their extensive research capabilities, regulatory approvals, and comprehensive marketing and distribution networks in the U.S. Their focus on biologics and targeted therapies, such as monoclonal antibodies, reflects the market trend toward precision medicine for severe asthma cases. The U.S. asthma drug market is growing rapidly, valued at about $8.95 billion in 2023 and forecast to exceed $14.75 billion by 2033, driven by increasing asthma prevalence and demand for advanced treatments. Their active engagement in clinical trials, innovative drug launches, and collaborations ensures ongoing leadership in this rapidly evolving field.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
